LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Начало・Списък с акции・Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

28.39 -0.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.15

Максимум

29.06

Ключови измерители
By Trading Economics
Приходи	-14M 17M
Продажби	17M 192M
P/E Средно за сектора	12.659 121.746
EPS	0.93
Марж на печалбата	9.044
Служители	2,028
EBITDA	-20M 42M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+11.85% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	154M 1.3B
Предишно отваряне	28.5
Предишно затваряне	28.39

Настроения в новините

By Acuity

68%

32%

316 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

23.91 / 25.04 Подкрепа & съпротива

Amphastar Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2026 г., 23:47 ч. UTC

Горещи акции

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11.02.2026 г., 22:59 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Grab Holdings to Buy U.S.-Based Stash Financial

11.02.2026 г., 23:54 ч. UTC

Печалби

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11.02.2026 г., 23:49 ч. UTC

Печалби

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11.02.2026 г., 23:45 ч. UTC

Печалби

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11.02.2026 г., 23:42 ч. UTC

Печалби

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11.02.2026 г., 23:41 ч. UTC

Печалби

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11.02.2026 г., 23:40 ч. UTC

Печалби

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11.02.2026 г., 23:18 ч. UTC

Пазарно говорене

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11.02.2026 г., 23:14 ч. UTC

Пазарно говорене

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11.02.2026 г., 22:58 ч. UTC

Печалби

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11.02.2026 г., 22:57 ч. UTC

Печалби

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11.02.2026 г., 22:54 ч. UTC

Печалби

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11.02.2026 г., 22:53 ч. UTC

Печалби

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:23 ч. UTC

Печалби

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11.02.2026 г., 22:19 ч. UTC

Печалби

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11.02.2026 г., 22:16 ч. UTC

Печалби

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Сравнение с други в отрасъла

Ценова промяна

Amphastar Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

11.85% нагоре

12-месечна прогноза

Среден 32 USD 11.85%

Висок 34 USD

Нисък 30 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Amphastar Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Amphastar Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.91 / 25.04Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

316 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.